Avadel Pharmaceuticals PLC
NASDAQ:AVDL
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
10.72
18.82
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one AVDL stock under the Base Case scenario is 19.65 USD. Compared to the current market price of 13.15 USD, Avadel Pharmaceuticals PLC is Undervalued by 33%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Avadel Pharmaceuticals PLC
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for AVDL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Avadel Pharmaceuticals PLC
Balance Sheet Decomposition
Avadel Pharmaceuticals PLC
Current Assets | 125.8m |
Cash & Short-Term Investments | 71.4m |
Receivables | 34.3m |
Other Current Assets | 20.1m |
Non-Current Assets | 31.7m |
PP&E | 2.6m |
Intangibles | 16.8m |
Other Non-Current Assets | 12.3m |
Current Liabilities | 44.6m |
Accounts Payable | 9.8m |
Accrued Liabilities | 34.6m |
Other Current Liabilities | 242k |
Non-Current Liabilities | 42.6m |
Other Non-Current Liabilities | 42.6m |
Earnings Waterfall
Avadel Pharmaceuticals PLC
Revenue
|
95.1m
USD
|
Cost of Revenue
|
-5.1m
USD
|
Gross Profit
|
90m
USD
|
Operating Expenses
|
-188.8m
USD
|
Operating Income
|
-98.8m
USD
|
Other Expenses
|
-7.4m
USD
|
Net Income
|
-106.2m
USD
|
Free Cash Flow Analysis
Avadel Pharmaceuticals PLC
USD | |
Free Cash Flow | USD |
Avadel Pharmaceuticals reported a 50% increase in revenue for Q2 2024, driven by strong demand for their narcolepsy drug LUMRYZ. Their net revenue soared to $41.5 million, with a gross profit of $38.7 million. Despite high operating expenses, Avadel is confident in maintaining operating income from Q3 onwards, leading up to an annual revenue of around $168 million. With over 1,900 patients on LUMRYZ and significant payer coverage, the company shows optimism in expanding its market share and meeting FDA's approval for pediatric narcolepsy treatment by September.
What is Earnings Call?
AVDL Profitability Score
Profitability Due Diligence
Avadel Pharmaceuticals PLC's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
Avadel Pharmaceuticals PLC's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
AVDL Solvency Score
Solvency Due Diligence
Avadel Pharmaceuticals PLC's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
Avadel Pharmaceuticals PLC's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AVDL Price Targets Summary
Avadel Pharmaceuticals PLC
According to Wall Street analysts, the average 1-year price target for AVDL is 25.09 USD with a low forecast of 20.2 USD and a high forecast of 31.5 USD.
Dividends
Current shareholder yield for AVDL is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
AVDL Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.
Contact
IPO
Employees
Officers
The intrinsic value of one AVDL stock under the Base Case scenario is 19.65 USD.
Compared to the current market price of 13.15 USD, Avadel Pharmaceuticals PLC is Undervalued by 33%.